News summaryCailian Press (CLS)Nov 1, 2026, 02:01 PM
Eli Lilly Beats Expectations and Raises Full-Year Revenue Guidance Again
U.S. innovative drug stocks continued to strengthen. [[fact-rno4fvvve]] Technology stocks declined. [[fact-rno4fvvve]] Eli Lilly's performance exceeded expectations. [[fact-tdinoxb2q]] Eli Lilly raised its full-year revenue guidance for the third time this year. [[fact-r17ax9u0q]] Domestic innovative drugs have also entered a stage of earnings validation. [[fact-h2gy2l7b9]]